Jean Bourhis

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


352 publications

... | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
2015
 
Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.
Economopoulou P., Bourhis J., Psyrri A., 2015. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting pp. e323-e328. Peer-reviewed.
[DOI][Pmid][serval:BIB_67B8AEDDA73E]
 
The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
Matzinger O., Viertl D., Tsoutsou P., Kadi L., Rigotti S., Zanna C., Wiedemann N., Vozenin M.C., Vuagniaux G., Bourhis J., 2015. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology, 116 (3) pp. 495-503. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BFF3A5A037D6]
 
Tumor-infiltrating lymphocytes in triple-negative breast cancer: a biomarker for use beyond prognosis?
Tsoutsou P.G., Bourhis J., Coukos G., 2015. Journal of Clinical Oncology, 33 (11) pp. 1297-1298. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0DCE380A0052]
2014
 
[(18)F]FDG-PET Standard Uptake Value as a Metabolic Predictor of Bone Marrow Response to Radiation: Impact on Acute and Late Hematological Toxicity in Cervical Cancer Patients Treated With Chemoradiation Therapy.
Elicin O., Callaway S., Prior J.O., Bourhis J., Ozsahin M., Herrera F.G., 2014. International Journal of Radiation Oncology, Biology, Physics, 90 (5) pp. 1099-1107. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9B5C992E8C1E]
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B., Bourhis J.P., Vermorken J.B., Harrington K.J., Cohen E.E., 2014. Trials, 15 p. 469.
[URN][DOI][WoS][Pmid][serval:BIB_BB40A9A07883]
 
Cancer du sein: radiothérapie et signalisation oestrogénique [Breast cancer: radiotherapy and estrogen signaling].
Bourgier C., Lemanski C., Romieu G., Ozsahin M., Azria D., 2014. Bulletin du Cancer, 101 (7-8) pp. 714-717. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E805CFB28C7C]
 
Carcinomes épidermoïdes de l'hypopharynx et du larynx : prise en charge fondée sur les preuves Squamous cell carcinoma of the hypopharynx and larynx: evidence-based care.
Fayette J., Pointreau Y., Bourhis J., Lefebvre J.L., 2014. Bulletin du Cancer, 101 (5) pp. 438-444. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C5F664096323]
 
Choline-PET in prostate cancer management: The point of view of the radiation oncologist.
De Bari B., Alongi F., Lestrade L., Giammarile F., 2014. Critical Reviews In Oncology/hematology, 91 (3) pp. 234-247. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_03EC902CE5FE]
 
Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlentherapie in Kombination mit platinbasierter Chemotherapie oder Cetuximab zur Behandlung von lokal fortgeschrittenen Plattenepithelkarzinomen im Kopf-Hals-Bereich.
Levy A., Blanchard P., Bellefqih S., Brahimi N., Guigay J., Janot F., Temam S., Bourhis J., Deutsch E., Daly-Schveitzer N. et al., 2014. Strahlentherapie Und Onkologie, 190 (9) pp. 823-831. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CAACDC1DE8DE]
 
Critères de qualité en radiothérapie des cancers de la tête et du cou sous l'égide de l'Intergroupe ORL Quality criteria in radiotherapy for head and neck cancers under the aegis of Head and Neck Intergroup.
Tao Y., Vintonenko N., Garcia R., Marchesi V., Tomsej M., Bardet E., Bourhis J., 2014. Bulletin du Cancer, 101 (5) pp. 481-485.
[DOI][WoS][Pmid][serval:BIB_F8617DF47057]
 
External beam radiotherapy ± chemotherapy in the treatment of anal canal cancer: a single-institute long-term experience on 100 patients.
De Bari B., Buglione M., Maddalo M., Lestrade L., Spiazzi L., Vitali P., Barbera F., Magrini S.M., 2014. Cancer Investigation, 32 (6) pp. 248-255. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A0906D2DB6A7]
 
Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A., Blanchard P., Bellefqih S., Brahimi N., Guigay J., Janot F., Temam S., Daly-Schveitzer N., Bourhis J., Tao Y., 2014. Anti-cancer Drugs, 25 (10) pp. 1220-1226. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9E0ACFD8EED0]
 
Four years with FALCON - an ESTRO educational project: achievements and perspectives.
Eriksen J.G., Salembier C., Rivera S., De Bari B., Berger D., Mantello G., Müller A.C., Martin A.N., Pasini D., Tanderup K. et al., 2014. Radiotherapy and Oncology, 112 (1) pp. 145-149. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3F19F2C3D80C]
 
From radiobiology to technology: what is changing in radiotherapy for prostate cancer.
De Bari B., Fiorentino A., Arcangeli S., Franco P., D'Angelillo R.M., Alongi F., 2014. Expert Review of Anticancer Therapy, 14 (5) pp. 553-564. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8A495E1A7F50]
 
Improving safety in radiotherapy: The implementation of the Global Risk Analysis method.
Mazeron R., Aguini N., Rivin E., Baudré A., Bour M.S., Dumas I., Hubert F., Lopes S., Desroches A., Deutsch E. et al., 2014. Radiotherapy and Oncolog, 112 (2) pp. 205-11. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ACA924E1AF30]
Long-term Outcome and Late Side Effects in Endometrial Cancer Patients Treated with Surgery and Postoperative Radiation Therapy.
Herrera F.G., Cruz O.S., Achtari C., Bourhis J., Ozsahin M., 2014. Annals of Surgical Oncology, 21 (7) pp. 2390-2397.
[URN][DOI][WoS][Pmid][serval:BIB_9652529431A0]
 
Prise en charge des cancers du cavum (rhinopharynx) Nasopharyngeal cancers, an overview.
Jardel P., Thariat J., Blanchard P., Elloumi F., Toumi N., Bensadoun R.J., Frikha M., Daoud J., Bourhis J., 2014. Bulletin du Cancer, 101 (5) pp. 445-454.
[DOI][WoS][Pmid][serval:BIB_0A629EE69270]
 
Reply to D. Tural et al.
Blanchard P., Bourhis J., Pignon J.P., 2014. Journal of Clinical Oncology, 32 (3) pp. 259-260.
[DOI][WoS][Pmid][serval:BIB_D9F530613565]
 
Salvage therapy of small volume prostate cancer nodal failures: a review of the literature.
De Bari B., Alongi F., Buglione M., Campostrini F., Briganti A., Berardi G., Petralia G., Bellomi M., Chiti A., Fodor A. et al., 2014. Critical Reviews In Oncology/hematology, 90 (1) pp. 24-35.
[DOI][Pmid][serval:BIB_0B81C14B4A93]
 
Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?. Plattenepithelkarzinom des Larynx mit subglottischer Ausdehnung: ist ein Larynxerhalt möglich ?
Levy A., Blanchard P., Temam S., Maison M.M., Janot F., Mirghani H., Bidault F., Guigay J., Lusinchi A., Bourhis J. et al., 2014. Strahlentherapie Und Onkologie, 190 (7) pp. 654-660. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A8FBB070D95E]
 
The PEDRO (Pocketable Electronic Devices in Radiation Oncology) project: how clinical practice is changing among young radiation oncologists.
De Bari B., Franco P., Ciammella P., Peruzzo Cornetto A., Greto D., Fundoni C., Filippi A.R., Alongi F., AIRO Giovani (Italian Association of Radiation Oncology-Young Members Working Group), 2014. Tumori, 100 (6) pp. 236e-242e. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B96681148BCF]
 
The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highlights from the 7th Meeting of AIRO - Young Members Working Group (AIRO Giovani).
Franco P., De Bari B., Ciammella P., Fiorentino A., Chiesa S., Amelio D., Pinzi V., Bonomo P., Vagge S., Fiore M. et al., 2014. Tumori, 100 (6) pp. 214e-229e. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4337AE01147]
 
Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice.
Favaudon V., Caplier L., Monceau V., Pouzoulet F., Sayarath M., Fouillade C., Poupon M.F., Brito I., Hupé P., Bourhis J. et al., 2014. Science Translational Medicine, 6 (245) pp. 245ra93. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6BEAFB335D2A]
2013
 
Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
Lartigau E.F., Tresch E., Thariat J., Graff P., Coche-Dequeant B., Benezery K., Schiappacasse L., Degardin M., Bondiau P.Y., Peiffert D. et al., 2013/11. Radiotherapy and Oncology, 109 (2) pp. 281-285. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB4E246EC6D3]
 
Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma.
Modesto A., Blanchard P., Tao Y.G., Rives M., Janot F., Serrano E., Benlyazid A., Guigay J., Ferrand F.R., Delord J.P. et al., 2013/08. Oral oncology, 49 (8) pp. 830-834. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B9074F682569]
 
Curiethérapie des cancers des voies aérodigestives supérieures [Brachytherapy for head and neck cancers]
Lapeyre M., Coche-Dequéant B., Moreira J.F., Le Bourhis J., Peiffert D., 2013/04. Cancer radiotherapie, 17 (2) pp. 130-135. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_780BB60DC647]
 
Nomograms predicting locoregional recurrence in the subtype era of breast cancer.
Tsoutsou P.G., Jeanneret Sozzi W., Matzinger O., Ozsahin M., 2013/02/10. Journal of clinical oncology, 31 (5) pp. 647-648. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EEB77FCDD35C]
 
Adenosquamous carcinoma of the head and neck: report of 20 cases and review of the literature.
Schick U., Pusztaszeri M., Betz M., Ghadjar P., Demiroz C., Kaanders J.H., Ozsahin M., 2013. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 116 (3) pp. 313-320. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8C325269EDBB]
 
Bio-radiation dermatitis: the need of a new grading: in regard to Bernier et al: Ann Oncol 2011; 22(10): 2191-2200.
Russi E.G., Bensadoun R.J., Merlano M.C., Bourhis J., Ricardi U., Giralt J., Pinto C., Budach W., Corvo R., Lacouture M.E. et al., 2013. Annals of Oncology, 24 (9) pp. 2463-2465.
[DOI][WoS][Pmid][serval:BIB_F81F450E1D31]
 
Centre de la prostate: une approche multidisciplinaire pour une prise en charge globale du patient [Prostate cancer center: a multidisciplinary approach to accurately manage patients with prostate cancer]
Tawadros T., Burruni R., Herrera F., Codeluppi C., Zurkinden C., Meuwly J.Y., Lhermitte B., Berthold D., 2013. Revue Médicale Suisse, 9 (409) pp. 2270-2, 2274.
[Pmid][serval:BIB_AA917B8978EC]
 
Evaluation of organ-specific peripheral doses after 2-dimensional, 3-dimensional and hybrid intensity modulated radiation therapy for breast cancer based on Monte Carlo and convolution/superposition algorithms: implications for secondary cancer risk assessment.
Joosten A., Matzinger O., Jeanneret-Sozzi W., Bochud F., Moeckli R., 2013/01. Radiotherapy and oncology, 106 (1) pp. 33-41. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2E35C2D6242A]
 
Immunothérapie: une nouvelle arme contre le cancer de la prostate [Immunotherapy: a therapeutic revolution against prostate cancer?].
Pracht M., Herrera F.G, Tawadros T., Berthold D., 2013. Revue Médicale Suisse, 9 (387) pp. 1070-1075. Peer-reviewed.
[Pmid][serval:BIB_872CCC33F242]
 
Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome.
Malouf G.G., Casiraghi O., Deutsch E., Guigay J., Temam S., Bourhis J., 2013. European Journal of Cancer, 49 (6) pp. 1324-1334.
[DOI][WoS][Pmid][serval:BIB_0A745D9C879D]
 
Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02.
Tao Y., Bardet E., Rosine D., Rolland F., Bompas E., Daly-Schveitzer N., Lusinchi A., Bourhis J., 2013. Radiation Oncology, 8 p. 40.
[DOI][WoS][Pmid][serval:BIB_7D7AAEA5DD02]
Prognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients.
Cai L., Mirimanoff R.O., Mouhsine E., Guillou L., Leyvraz P.F., Leyvraz S., Gay B., Matzinger O., Ozsahin M., Zouhair A., 2013. Rare Tumors, 5 (4) pp. e55. Peer-reviewed.
[DOI][Pmid][serval:BIB_4B29ECFF32A1]
 
Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting.
De Bari B., Fiorentino A., Greto D., Ciammella P., Arcangeli S., Avuzzi B., D'Angelillo R.M., Desideri I., Kirienko M., Marchiori D. et al., 2013. Tumori, 99 (6) pp. 637-649. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EEE7315FFC10]
 
Radiosensibilité individuelle : les tests vont changer nos pratiques [Intrinsic radiosensitivity: predictive assays that will change the daily practice].
Lacombe J., Riou O., Solassol J., Mangé A., Bourgier C., Fenoglietto P., Pèlegrin A., Ozsahin M., Azria D., 2013. Cancer Radiothérapie, 17 (5-6) pp. 337-343.
[DOI][WoS][Pmid][serval:BIB_31527A9EF138]
 
Radiotherapy options after breast-conserving surgery: how can selection of patients be refined?
Tsoutsou P.G., Jeanneret Sozzi W., Ozsahin M., Delaloye J.F., Bourhis J., 2013. Journal of Clinical Oncology, 31 (36) pp. 4570-4571. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C8D10DF8C575]
Retrospective feasibility study of simultaneous integrated boost in cervical cancer using Tomotherapy: the impact of organ motion and tumor regression.
Herrera F.G., Callaway S., Delikgoz-Soykut E., Coskun M., Porta L., Meuwly J.Y., Soares-Rodrigues J., Heym L., Moeckli R., Ozsahin M., 2013. Radiation Oncology, 8 (5) pp. 1-10. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A4AEBB0F5438]
 
Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
Blanchard P., Bourhis J., Lacas B., Posner M.R., Vermorken J.B., Hernandez J.J., Bourredjem A., Calais G., Paccagnella A., Hitt R. et al., 2013. Journal of Clinical Oncology, 31 (23) pp. 2854-2860.
[DOI][WoS][Pmid][serval:BIB_CFC3A3756309]
The role of PET/CT in cervical cancer.
Herrera F.G., Prior J.O., 2013. Frontiers in Oncology, 3 p. 34.
[URN][DOI][Pmid][serval:BIB_A37E9045E6C9]
The use of PET/CT in radiotherapy planning: contribution of deformable registration.
Delikgoz Soykut E., Ozsahin E.M., Yukselen Guney Y., Aytac Arslan S., Derinalp Or O., Altundag M.B., Ugurluer G., Tsoutsou P.G., 2013. Frontiers In Oncology, 3 p. 33. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_C6E2180DCFA9]
2012
 
Absent benefit of accelerated concomitant chemoradiotherapy.
Prestwich R.J., Sen M., 2012/04. The Lancet. Oncology, 13 (4) pp. e136; author reply e136-7. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6433975567A9]
 
Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy.
Clémenson C., Chargari C., Désiré L., Casagrande A.S., Bourhis J., Deutsch E., 2012. Investigational New Drugs, 30 (6) pp. 2173-2186. Peer-reviewed.
[DOI][Pmid][serval:BIB_E9D542C7BF39]
 
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J., Sire C., Graff P., Grégoire V., Maingon P., Calais G., Gery B., Martin L., Alfonsi M., Desprez P. et al., 2012. Lancet Oncology, 13 (2) pp. 145-153. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_832A983D2A62]
 
Definitive organ-sparing treatment of anal canal cancer: can we afford to question it?
Ozsahin M., Santa Cruz O., Bouchaab H., Matzinger O., Tsoutsou P.G., 2012. Journal of Clinical Oncology, 30 (6) pp. 673-675.
[DOI][WoS][Pmid][serval:BIB_0DC9B2091652]
 
Definitive radiotherapy for squamous cell carcinoma of the pyriform sinus.
Blanchard P., Tao Y., Veresezan O., Lusinchi A., Le Ridant A.M., Janot F., Daly-Schveitzer N., Bourhis J., 2012. Radiotherapy and Oncology, 105 (2) pp. 232-237. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5C6047924C6E]
 
ESTRO 2012 strategy meeting: vision for radiation oncology.
Valentini V., Bourhis J., Hollywood D., 2012. Radiotherapy and Oncology, 103 (1) pp. 99-102. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_33A16A4E87CF]
 
Heterogeneous telomere defects in patients with severe forms of dyskeratosis congenita.
Touzot F., Gaillard L., Vasquez N., Le Guen T., Bertrand Y., Bourhis J., Leblanc T., Fischer A., Soulier J., de Villartay J.P. et al., 2012. Journal of Allergy and Clinical Immunology, 129 (2) pp. 473-82, 482.e1-3. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E2B2A5238B91]
 
Nanoscale radiotherapy with hafnium oxide nanoparticles.
Maggiorella L., Barouch G., Devaux C., Pottier A., Deutsch E., Bourhis J., Borghi E., Levy L., 2012. Future Oncology, 8 (9) pp. 1167-1181. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D5B05C8A194B]
 
Retreatment of recurrent head and neck cancer in a previously irradiated field.
Wong S.J., Bourhis J., Langer C.J., 2012. Seminars in Radiation Oncology, 22 (3) pp. 214-219. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_61BE68C8B3AF]
The Rare Cancer Network: achievements from 1993 to 2012.
Patel A., Ozsahin M., Mirimanoff R.O., Bhatia S., Chang K., Miller R.C., 2012. Rare Tumors, 4 (3) pp. e35.
[URN][DOI][Pmid][serval:BIB_29A86767B2F1]
2011
 
Modulation pharmacologique des effets tardifs de l'irradiation [Pharmacological modulation of late radio-induced side effects]
Bourgier C., Monceau V., Bourhis J., Deutsch E., Vozenin M.C., 2011/08. Cancer radiotherapie, 15 (5) pp. 383-389. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC8DA0FDD168]
 
A new method of assessing the dose-carcinogenic effect relationship in patients exposed to ionizing radiation. A concise presentation of preliminary data.
Tubiana M., Diallo I., Chavaudra J., Lefkopoulos D., Bourhis J., Girinsky T., Brider A., Hawkins M., Haddy N., El-Fayech C. et al., 2011. Health Physics, 100 (3) pp. 296-299. Peer-reviewed.
[Pmid][serval:BIB_10DF9A4F84BE]
 
A phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Tao Y., Rezaï K., Brain E., Etessami A., Lusinchi A., Temam S., Urien S., Van M.L., Vauzelle-Kervroedan F., Lokiec F. et al., 2011. Radiotherapy and Oncology, 98 (1) pp. 42-47. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4CE4DCBC4554]
 
Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial.
Bourhis J., Lapeyre M., Tortochaux J., Lusinchi A., Etessami A., Ducourtieux M., Geoffrois L., Domenge C., Verrelle P., Wibault P. et al., 2011. Radiotherapy and Oncology, 100 (1) pp. 56-61.
[DOI][WoS][Pmid][serval:BIB_FA016A07A77B]
 
Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.
Itzhar N., Dessen P., Toujani S., Auger N., Preudhomme C., Richon C., Lazar V., Saada V., Bennaceur A., Bourhis J.H. et al., 2011. Plos One, 6 (2) pp. e16623. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_68B9F202E56E]
 
Early side effects of three-dimensional conformal external beam accelerated partial breast irradiation to a total dose of 40 Gy in one week (a phase II trial).
Bourgier C., Pichenot C., Verstraet R., El Nemr M., Heymann S., Biron B., Delaloge S., Mathieu M.C., Garbay J.R., Bourhis J. et al., 2011. International Journal of Radiation Oncology, Biology, Physics, 81 (5) pp. 1228-1235. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EA7AC9923CB4]
 
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Bourhis J., Blanchard P., Maillard E., Brizel D.M., Movsas B., Buentzel J., Langendijk J.A., Komaki R., Swan Leong S., Levendag P. et al., 2011. Journal of Clinical Oncology, 29 (18) pp. 2590-2597. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_887EC15BAE4A]
 
IMRT or conformal radiotherapy for adjuvant treatment of retroperitoneal sarcoma?
Paumier A., Le Péchoux C., Beaudré A., Negretti L., Ferreira I., Roberti E., Brahim J., Lefkopoulos D., Daly-Schweitzer N., Bourhis J. et al., 2011. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology, 99 (1) pp. 73-78. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E6C213BE8D9]
 
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.
Blanchard P., Baujat B., Holostenco V., Bourredjem A., Baey C., Bourhis J., Pignon J.P., MACH-CH Collaborative group, 2011. Radiotherapy and Oncology, 100 (1) pp. 33-40. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7AF74E882B01]
 
Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer.
Blanchard P., Hill C., Guihenneuc-Jouyaux C., Baey C., Bourhis J., Pignon J.P., MACH-NC , MARCH Collaborative Groups, 2011. Journal of Clinical Epidemiology, 64 (9) pp. 985-992.
[DOI][WoS][Pmid][serval:BIB_DCC11F6E4F83]
 
New techniques in radiation therapy for head and neck cancer: IMRT, CyberKnife, protons, and carbon ions. Improved effectiveness and safety? Impact on survival?
Thariat J., Bolle S., Demizu Y., Marcy P.Y., Hu Y., Santini J., Bourhis J., Pommier P., 2011. Anti-cancer Drugs, 22 (7) pp. 596-606. Peer-reviewed.
[DOI][Pmid][serval:BIB_1CFC3360ADAA]
 
Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.
Chargari C., Leteur C., Angevin E., Bashir T., Schoentjes B., Arts J., Janicot M., Bourhis J., Deutsch E., 2011. Cancer Letters, 312 (2) pp. 209-218. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CC55BE91B23B]
 
Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent.
Tortochaux J., Tao Y., Tournay E., Lapeyre M., Lesaunier F., Bardet E., Janot F., Lusinchi A., Benhamou E., Bontemps P. et al., 2011. Radiotherapy and Oncology, 100 (1) pp. 70-75. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6084BE15DE85]
 
Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial.
Bardet E., Martin L., Calais G., Alfonsi M., Feham N.E., Tuchais C., Boisselier P., Dessard-Diana B., Seng S.H., Garaud P. et al., 2011. Journal of Clinical Oncology, 29 (2) pp. 127-133. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F5C74FCB1B42]
2010
 
Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas.
Dhermain F., Saliou G., Parker F., Page P., Hoang-Xuan K., Lacroix C., Tournay E., Bourhis J., Ducreux D., 2010/03. Journal of neuro-oncology, 97 (1) pp. 81-88. Peer-reviewed.
[DOI][Pmid][serval:BIB_9A1708CEC903]
 
Advances in radiotherapy of head and neck cancers.
Tao Y., Daly-Schveitzer N., Lusinchi A., Bourhis J., 2010. Current Opinion In Oncology, 22 (3) pp. 194-199. Peer-reviewed.
[WoS][Pmid][serval:BIB_BB4005BBD2B6]
 
Cetuximab in the management of locoregionally advanced head and neck cancer: expanding the treatment options?
Bourhis J., Lefebvre J.L., Vermorken J.B., 2010. European Journal of Cancer, 46 (11) pp. 1979-1989. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1333A1E526AF]
 
Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.
Peters L.J., O'Sullivan B., Giralt J., Fitzgerald T.J., Trotti A., Bernier J., Bourhis J., Yuen K., Fisher R., Rischin D., 2010. Journal of Clinical Oncology, 28 (18) pp. 2996-3001. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D857950C8DE2]
 
Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
Loriot Y., Mordant P., Brown B.D., Bourhis J., Soria J.C., Deutsch E., 2010. Anticancer Research, 30 (10) pp. 3869-3878. Peer-reviewed.
[WoS][Pmid][serval:BIB_D9F4C2EB3936]
 
Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.
Tukenova M., Guibout C., Oberlin O., Doyon F., Mousannif A., Haddy N., Guérin S., Pacquement H., Aouba A., Hawkins M. et al., 2010. Journal of Clinical Oncology, 28 (8) pp. 1308-1315. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C96B47BEFCA8]
 
Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas - stratification for postsalvage survival.
Tan H.K., Giger R., Auperin A., Bourhis J., Janot F., Temam S., 2010. Head and Neck, 32 (2) pp. 139-147. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7626BEC7807]
 
Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
Rischin D., Peters L.J., O'Sullivan B., Giralt J., Fisher R., Yuen K., Trotti A., Bernier J., Bourhis J., Ringash J. et al., 2010. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28 (18) pp. 2989-2995. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_254263E47B00]
 
What have we learned from human papillomavirus-positive tumors? Trying to connect data about biomarkers among human papillomavirus-related squamous cell carcinomas.
Vozenin M.C., Bourhis J., Deutsch E., 2010. Journal of Clinical Oncology, 28 (20) pp. e340-1; author reply e342. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4934725FB098]
2009
 
A pre-clinical assessment of an atlas-based automatic segmentation tool for the head and neck.
Sims R., Isambert A., Grégoire V., Bidault F., Fresco L., Sage J., Mills J., Bourhis J., Lefkopoulos D., Commowick O. et al., 2009. Radiotherapy and Oncology, 93 (3) pp. 474-478. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F35ECDE0804]
 
Current concepts of management in radiotherapy for head and neck squamous-cell cancer.
Mazeron R., Tao Y., Lusinchi A., Bourhis J., 2009. Oral Oncology, 45 (4-5) pp. 402-408. Peer-reviewed.
[DOI][Pmid][serval:BIB_2B516D15FE9F]
 
Differential effect triggered by a heparan mimetic of the RGTA family preventing oral mucositis without tumor protection.
Mangoni M., Yue X., Morin C., Violot D., Frascogna V., Tao Y., Opolon P., Castaing M., Auperin A., Biti G. et al., 2009. International Journal of Radiation Oncology, Biology, Physics, 74 (4) pp. 1242-1250. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_70926D11B414]
 
Interfractional set-up errors evaluation by daily electronic portal imaging of IMRT in head and neck cancer patients.
Pehlivan B., Pichenot C., Castaing M., Auperin A., Lefkopoulos D., Arriagada R., Bourhis J., 2009. Acta Oncologica, 48 (3) pp. 440-445. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1B809A69621E]
 
Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary.
Lefebvre J.L., Ang K.K., Larynx Preservation Consensus Panel, 2009. Head and Neck, 31 (4) pp. 429-441. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9D4D4F9AD0AC]
 
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.
Pignon J.P., le Maître A., Maillard E., Bourhis J., MACH-NC Collaborative Group, 2009. Radiotherapy and Oncology, 92 (1) pp. 4-14. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_339C5559D67C]
 
Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells.
Amine A., Rivera S., Opolon P., Dekkal M., Biard D.S., Bouamar H., Louache F., McKay M.J., Bourhis J., Deutsch E. et al., 2009. Plos One, 4 (3) pp. e5018. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1CCD97CFE8E0]
 
Oral cavity squamous cell carcinoma in 260 patients aged 80years or more.
Ortholan C., Lusinchi A., Italiano A., Bensadoun R.J., Auperin A., Poissonnet G., Bozec A., Arriagada R., Temam S., Benezery K. et al., 2009. Radiotherapy and Oncology, 93 (3) pp. 516-523. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF3E2D6B9415]
 
Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Harrington K.J., El-Hariry I.A., Holford C.S., Lusinchi A., Nutting C.M., Rosine D., Tanay M., Deutsch E., Matthews J., D'Ambrosio C. et al., 2009. Journal of Clinical Oncology, 27 (7) pp. 1100-1107. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_240DC9235492]
 
Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.
Tao Y., Leteur C., Yang C., Zhang P., Castedo M., Pierré A., Golsteyn R.M., Bourhis J., Kroemer G., Deutsch E., 2009. Cell Cycle, 8 (8) pp. 1196-1205. Peer-reviewed.
[WoS][Pmid][serval:BIB_6D8E573DA590]
 
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Michiels S., Le Maître A., Buyse M., Burzykowski T., Maillard E., Bogaerts J., Vermorken J.B., Budach W., Pajak T.F., Ang K.K. et al., 2009. Lancet. Oncology, 10 (4) pp. 341-350. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2F7598029DC7]
 
The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
Tao Y., Leteur C., Calderaro J., Girdler F., Zhang P., Frascogna V., Varna M., Opolon P., Castedo M., Bourhis J. et al., 2009. Cell Cycle, 8 (19) pp. 3172-3181. Peer-reviewed.
[WoS][Pmid][serval:BIB_EB362FCFA11D]
2008
 
Botulinum toxin for radiation-induced facial pain and trismus.
Hartl D.M., Cohen M., Juliéron M., Marandas P., Janot F., Bourhis J., 2008. Otolaryngology--head and Neck Surgery, 138 (4) pp. 459-463. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CC30657C241E]
 
Comparison of dose contribution to normal pelvic tissues among conventional, conformal and intensity-modulated radiotherapy techniques in prostate cancer.
Tao Y., Lefkopoulos D., Ibrahima D., Bridier A., Polizzi Mdel P, Wibault P., De Crevoisier R., Arriagada R., Bourhis J., 2008. Acta Oncologica, 47 (3) pp. 442-450. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_37367FDFDE35]
 
Distant metastasis of undifferentiated carcinoma of nasopharyngeal type.
Tao Y., Bidault F., Bosq J., Bourhis J., 2008. Onkologie, 31 (11) pp. 574-575. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E500B2E87584]
 
Molecular profiling of uterine cervix carcinoma: an overview with a special focus on rationally designed target-based anticancer agents.
Magné N., Chargari C., Deutsch E., Castadot P., Ghalibafian M., Bourhis J., Haie-Meder C., 2008. Cancer Metastasis Reviews, 27 (4) pp. 737-750. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_16E10548221D]
 
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Janot F., de Raucourt D., Benhamou E., Ferron C., Dolivet G., Bensadoun R.J., Hamoir M., Géry B., Julieron M., Castaing M. et al., 2008. Journal of Clinical Oncology, 26 (34) pp. 5518-5523. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7B0F38DD4120]
 
Targeted therapies in head and neck cancer: past, present and future.
Rapidis A.D., Vermorken J.B., Bourhis J., 2008. Reviews on Recent Clinical Trials, 3 (3) pp. 156-166.
[Pmid][serval:BIB_0E7D206021E9]
 
The efficacy and toxicity of EGFR in the settings of radiotherapy: focus on published clinical trials.
Magné N., Chargari C., Castadot P., Ghalibafian M., Soria J.C., Haie-Meder C., Bourhis J., Deutsch E., 2008. European Journal of Cancer, 44 (15) pp. 2133-2143. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E877F7604DFF]
2007
 
Glucagon-like peptide-2 improves both acute and late experimental radiation enteritis in the rat.
Torres S., Thim L., Milliat F., Vozenin-Brotons M.C., Olsen U.B., Ahnfelt-Rønne I., Bourhis J., Benderitter M., François A., 2007. International Journal of Radiation Oncology, Biology, Physics, 69 (5) pp. 1563-1571.
[DOI][WoS][Pmid][serval:BIB_3CDB1112D7B7]
 
Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy.
Graff P., Lapeyre M., Desandes E., Ortholan C., Bensadoun R.J., Alfonsi M., Maingon P., Giraud P., Bourhis J., Marchesi V. et al., 2007. International Journal of Radiation Oncology, Biology, Physics, 67 (5) pp. 1309-1317. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_26D432BC34DC]
 
Implications of learning effects for hospital costs of new health technologies: the case of intensity modulated radiation therapy.
Bonastre J., Noël E., Chevalier J., Gerard J.P., Lefkopoulos D., Bourhis J., Bensadoun R.J., de Pouvourville G., STIC IMRT 2002 Investigators, 2007. International Journal of Technology Assessment In Health Care, 23 (2) pp. 248-254.
[DOI][WoS][Pmid][serval:BIB_225A07D2586C]
 
Individual patients' data meta-analyses in head and neck cancer.
Bourhis J., Le Maître A., Baujat B., Audry H., Pignon J.P., Meta-Analysis of Chemotherapy in Head Neck Cancer Collaborative Group, Meta-Analysis of Radiotherapy in Carcinoma of Head Neck Collaborative Group, Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma Collaborative Group, 2007. Current Opinion in Oncology, 19 (3) pp. 188-194. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D0991F3B098A]
 
Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
Tao Y., Pinzi V., Bourhis J., Deutsch E., 2007. Nature Clinical Practice. Oncology, 4 (10) pp. 591-602. Peer-reviewed.
[DOI][Pmid][serval:BIB_014E76B11FEE]
 
Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update.
Pignon J.P., le Maître A., Bourhis J., MACH-NC Collaborative Group, 2007. International Journal of Radiation Oncology, Biology, Physics, 69 (2 Suppl) pp. S112-S114. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A88CA6AA179C]
 
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
Cohen E.E., Rosine D., Haraf D.J., Loh E., Shen L., Lusinchi A., Vokes E.E., Bourhis J., 2007. International Journal of Radiation Oncology, Biology, Physics, 67 (3) pp. 678-684. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9158A41C9974]
 
Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats.
Haydont V., Bourgier C., Pocard M., Lusinchi A., Aigueperse J., Mathé D., Bourhis J., Vozenin-Brotons M.C., 2007. Clinical Cancer Research, 13 (18 Pt 1) pp. 5331-5340. Peer-reviewed.
[DOI][Pmid][serval:BIB_42D263856D68]
 
Reirradiation in squamous cell head and neck cancer: recent developments and future directions.
Langendijk J.A., Bourhis J., 2007. Current Opinion in Oncology, 19 (3) pp. 202-209. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E1985ABB270C]
 
Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection.
Haydont V., Gilliot O., Rivera S., Bourgier C., François A., Aigueperse J., Bourhis J., Vozenin-Brotons M.C., 2007. International Journal of Radiation Oncology, Biology, Physics, 68 (5) pp. 1471-1482. Peer-reviewed.
[DOI][Pmid][serval:BIB_9D918D402FE9]
 
Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers.
M'kacher R., Bennaceur-Griscelli A., Girinsky T., Koscielny S., Delhommeau F., Dossou J., Violot D., Leclercq E., Courtier M.H., Béron-Gaillard N. et al., 2007. International Journal of Radiation Oncology, Biology, Physics, 68 (2) pp. 465-471. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2C7EC4261439]
 
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P. et al., 2007. Nature Medicine, 13 (9) pp. 1050-1059. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_131A9EB0C182]
2006
 
Caspase independence of radio-induced cell death.
Zhang P., Castedo M., Tao Y., Violot D., Métivier D., Deutsch E., Kroemer G., Bourhis J., 2006. Oncogene, 25 (59) pp. 7758-7770.
[DOI][WoS][Pmid][serval:BIB_E26EE6727B61]
 
Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients.
Baujat B., Audry H., Bourhis J., Chan A.T., Onat H., Chua D.T., Kwong D.L., Al-Sarraf M., Chi K.H., Hareyama M. et al., 2006. International Journal of Radiation Oncology, Biology, Physics, 64 (1) pp. 47-56. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EA3BAB1C0926]
 
Cidofovir administered with radiation displays an antiangiogenic effect mediated by E6 inhibition and subsequent TP53-dependent VEGF repression in HPV18+ cell lines.
Amine A., Vozenin-Brotons M.C., Abdulkarim B., Violot D., Aubel C., Bourhis J., 2006. Radiation Research, 166 (4) pp. 600-610. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EDE26817A378]
 
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.
Bourhis J., Overgaard J., Audry H., Ang K.K., Saunders M., Bernier J., Horiot J.C., Le Maître A., Pajak T.F., Poulsen M.G. et al., 2006. Lancet, 368 (9538) pp. 843-854. Peer-reviewed.
[DOI][Pmid][serval:BIB_16E774B6AA79]
 
Hypoxia response pathways and radiotherapy for head and neck cancer.
Bourhis J., 2006. Journal of Clinical Oncology, 24 (5) pp. 725-726. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8AAC0108BB64]
 
Influence of endothelial cells on vascular smooth muscle cells phenotype after irradiation: implication in radiation-induced vascular damages.
Milliat F., François A., Isoir M., Deutsch E., Tamarat R., Tarlet G., Atfi A., Validire P., Bourhis J., Sabourin J.C. et al., 2006. American Journal of Pathology, 169 (4) pp. 1484-1495. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B2CBD69D8EDE]
 
Le coût de la radiothérapie conformationnelle avec modulation d'intensité dans les cancers ORL: l'étude STIC 2002 [The cost of intensity modulated radiation therapy in head and neck cancers: results of the 2002 STIC study].
Bonastre M.J., Noël E., Bensadoun R.J., Chapet O., Favrel V., Dubois J.B., Ailleres N., Giraud P., Lefkopoulos D., Marcié S. et al., 2006. Bulletin du Cancer, 93 (10) pp. 1026-1032. Peer-reviewed.
[Pmid][serval:BIB_4E7583CF835C]
 
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J., Rivera F., Mesia R., Awada A., Geoffrois L., Borel C., Humblet Y., Lopez-Pousa A., Hitt R., Vega Villegas M.E. et al., 2006. Journal of Clinical Oncology, 24 (18) pp. 2866-2872. Peer-reviewed.
[DOI][Pmid][serval:BIB_86450352562D]
 
Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial.
Bourhis J., Lapeyre M., Tortochaux J., Rives M., Aghili M., Bourdin S., Lesaunier F., Benassi T., Lemanski C., Geoffrois L. et al., 2006. Journal of Clinical Oncology, 24 (18) pp. 2873-2878. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_93835B0029BA]
 
Therapeutic protein transduction of mammalian cells and mice by nucleic acid-free lentiviral nanoparticles.
Link N., Aubel C., Kelm J.M., Marty R.R., Greber D., Djonov V., Bourhis J., Weber W., Fussenegger M., 2006. Nucleic Acids Research, 34 (2) pp. e16. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9DA94534ECE8]
2005
 
Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression.
Bourgier C., Haydont V., Milliat F., François A., Holler V., Lasser P., Bourhis J., Mathé D., Vozenin-Brotons M.C., 2005/03. Gut, 54 (3) pp. 336-343. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D9483C6526A4]
 
Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion.
Kaliski A., Maggiorella L., Cengel K.A., Mathe D., Rouffiac V., Opolon P., Lassau N., Bourhis J., Deutsch E., 2005. Molecular Cancer Therapeutics, 4 (11) pp. 1717-1728. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A64704746F6A]
 
Associations chimioradiothérapie chez les patientes atteintes d'un carcinome du col utérin [Concomitant chemoradiation in patients with cervix cancer].
Haie-Meder C., de Crevoisier R., Bruna A., Lhommé C., Pautier P., Morice P., Castaigne D., Bourhis J., 2005. Bulletin du Cancer, 92 (12) pp. 1032-1038. Peer-reviewed.
[Pmid][serval:BIB_9296BF8AC25C]
 
Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model.
Maggiorella L., Wen B., Frascogna V., Opolon P., Bourhis J., Deutsch E., 2005. Anticancer Research, 25 (6B) pp. 4357-4362. Peer-reviewed.
[WoS][Pmid][serval:BIB_0A234F98FD6C]
 
Concurrent radio-chemotherapy combination in patients with advanced head and neck squamous cell carcinoma.
Bourhis J., 2005. Onkologie, 28 (10) pp. 473-474. Peer-reviewed.
[WoS][Pmid][serval:BIB_B291C12D4DC7]
 
Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives.
Haydont V., Mathé D., Bourgier C., Abdelali J., Aigueperse J., Bourhis J., Vozenin-Brotons M.C., 2005. Radiotherapy and Oncology, 76 (2) pp. 219-225. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB7ECC52C38A]
 
Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting.
West C.M., McKay M.J., Hölscher T., Baumann M., Stratford I.J., Bristow R.G., Iwakawa M., Imai T., Zingde S.M., Anscher M.S. et al., 2005. International Journal of Radiation Oncology, Biology, Physics, 62 (5) pp. 1264-1273. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5D930AB34A15]
 
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J., Trigo J.M., Bourhis J., Tortochaux J., Cortés-Funes H., Hitt R., Gascón P., Amellal N., Harstrick A., Eckardt A., 2005. Journal of Clinical Oncology, 23 (24) pp. 5568-5577. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EECC021AF6EB]
 
Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma.
Temam S., Pape E., Janot F., Wibault P., Julieron M., Lusinchi A., Mamelle G., Marandas P., Luboinski B., Bourhis J., 2005. International Journal of Radiation Oncology, Biology, Physics, 62 (4) pp. 1078-1083. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_67498C8D25BB]
 
Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma.
Temam S., Koka V., Mamelle G., Julieron M., Carmantrant R., Marandas P., Janot F., Bourhis J., Luboinski B., 2005. Head and Neck, 27 (8) pp. 653-658.
[DOI][Pmid][serval:BIB_A28DB213F1B2]
2004
 
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
Deutsch E., Maggiorella L., Wen B., Bonnet M.L., Khanfir K., Frascogna V., Turhan A.G., Bourhis J., 2004/11/01. British journal of cancer, 91 (9) pp. 1735-1741. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DA6835983ED6]
 
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer
Bernier J., Domenge C., Ozsahin M., Matuszewska K., Lefebvre J. L., Greiner R. H., Giralt J., Maingon P., Rolland F., Bolla M. et al., 2004/05. New England Journal of Medicine, 350 (19) pp. 1945-52. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7D5E10EB0204]
 
A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy.
Trotti A., Garden A., Warde P., Symonds P., Langer C., Redman R., Pajak T.F., Fleming T.R., Henke M., Bourhis J. et al., 2004. International Journal of Radiation Oncology, Biology, Physics, 58 (3) pp. 674-681. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B6C892BDE0BB]
 
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck.
Pignon J.P., Syz N., Posner M., Olivares R., Le Lann L., Yver A., Dunant A., Lewin F., Dalley D.N., Paccagnella A. et al., 2004. Anti-cancer Drugs, 15 (4) pp. 331-340. Peer-reviewed.
[WoS][Pmid][serval:BIB_930FECCEA70F]
 
Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations.
Bourhis J., Etessami A., Wilbault P., Lusinchi A., Calais G., Lapeyre M., Pignon J.P., 2004. Current Opinion in Oncology, 16 (3) pp. 215-219. Peer-reviewed.
[WoS][Pmid][serval:BIB_FF29A9470DFE]
 
Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
Boccia R., Anné P.R., Bourhis J., Brizel D., Daly C., Holloway N., Hymes S., Koukourakis M., Kozloff M., Turner M. et al., 2004. International Journal of Radiation Oncology, Biology, Physics, 60 (1) pp. 302-309. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB8808099EA7]
 
Environmental, genetic, and molecular features of prostate cancer.
Deutsch E., Maggiorella L., Eschwege P., Bourhis J., Soria J.C., Abdulkarim B., 2004. Lancet. Oncology, 5 (5) pp. 303-313. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_55FC7D90AAEC]
 
Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization.
Vozenin-Brotons M.C., Milliat F., Linard C., Strup C., François A., Sabourin J.C., Lasser P., Lusinchi A., Deutsch E., Girinsky T. et al., 2004. Radiation Research, 161 (3) pp. 299-311. Peer-reviewed.
[WoS][Pmid][serval:BIB_057E912DFE73]
 
Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis.
Strup-Perrot C., Mathé D., Linard C., Violot D., Milliat F., François A., Bourhis J., Vozenin-Brotons M.C., 2004. American Journal of Physiology. Gastrointestinal and Liver Physiology, 287 (4) pp. G875-G885.
[DOI][WoS][Pmid][serval:BIB_C31EEB1C70E9]
 
Quantified relationship between cellular radiosensitivity, DNA repair defects and chromatin relaxation: a study of 19 human tumour cell lines from different origin.
Chavaudra N., Bourhis J., Foray N., 2004. Radiotherapy and Oncology, 73 (3) pp. 373-382. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0308595603AC]
 
Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial.
Calais G., Bardet E., Sire C., Alfonsi M., Bourhis J., Rhein B., Tortochaux J., Man Y.T., Auvray H., Garaud P., 2004. International Journal of Radiation Oncology, Biology, Physics, 58 (1) pp. 161-166. Peer-reviewed.
[WoS][Pmid][serval:BIB_93644BFEDE8F]
 
Récidives locorégionales des carcinomes des voies aérodigestives supérieures: place des ré-irradiations [Locoregional recurrences of HNSCC: place of re-irradiations].
Bourhis J., Temam S., Wibault P., Lusinchi A., de Crevoisier B., Janot R., Bobin S., 2004. Bulletin du Cancer, 91 (11) pp. 871-873. Peer-reviewed.
[Pmid][serval:BIB_D0A95918C6CA]
2003
 
Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B., Sabri S., Zelenika D., Deutsch E., Frascogna V., Klijanienko J., Vainchenker W., Joab I., Bourhis J., 2003. Oncogene, 22 (15) pp. 2260-2271. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_840EEEDB0950]
 
Ciblage du récepteur du facteur de croissance épidermique et applications en cancérologie ORL [Targeting of epidermal growth factor receptor and applications in ORL cancer].
Tortochaux J., Aunoble B., Rolhion C., Bourhis J., 2003. Bulletin du Cancer, 90 (Spec No) pp. S220-S227.
[Pmid][serval:BIB_ED20DA2112B6]
 
Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
Wen B., Deutsch E., Eschwege P., De Crevoisier R., Nasr E., Eschwege F., Bourhis J., 2003. Journal of Urology, 170 (5) pp. 2036-2039. Peer-reviewed.
[DOI][Pmid][serval:BIB_92772F6F7522]
 
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Deutsch E., Jarrousse S., Buet D., Dugray A., Bonnet M.L., Vozenin-Brotons M.C., Guilhot F., Turhan A.G., Feunteun J., Bourhis J., 2003. Blood, 101 (11) pp. 4583-4588.
[DOI][WoS][Pmid][serval:BIB_40636655F867]
 
Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Maggiorella L., Deutsch E., Frascogna V., Chavaudra N., Jeanson L., Milliat F., Eschwege F., Bourhis J., 2003. Cancer Research, 63 (10) pp. 2513-2517. Peer-reviewed.
[WoS][Pmid][serval:BIB_EE6F15D78480]
 
Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression.
Vozenin-Brotons M.C., Milliat F., Sabourin J.C., de Gouville A.C., François A., Lasser P., Morice P., Haie-Meder C., Lusinchi A., Antoun S. et al., 2003. International Journal of Radiation Oncology, Biology, Physics, 56 (2) pp. 561-572. Peer-reviewed.
[WoS][Pmid][serval:BIB_15D841A8F4B0]
 
Sensitivity to radiation and alkylating agent of peripheral lymphocytes and fibroblasts in a Hoyeraal-Hreidarsson syndrome patient.
M'kacher R., Laithier V., Valent A., Delhommeau F., Violot D., Deutsch E., Dossou J., Béron-Gaillard N., Girinsky T., Bourhis J. et al., 2003. Pediatric Hematology and Oncology, 20 (8) pp. 651-656. Peer-reviewed.
[WoS][Pmid][serval:BIB_3FDA1C797AE2]
2002
 
Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.
Abdulkarim B., Sabri S., Deutsch E., Chagraoui H., Maggiorella L., Thierry J., Eschwege F., Vainchenker W., Chouaïb S., Bourhis J., 2002. Oncogene, 21 (15) pp. 2334-2346. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D37A37101F7D]
 
Chromosomal aberrations induced by chemotherapy and radiotherapy in lymphocytes from patients with breast carcinoma.
Légal J.D., De Crevoisier R., Lartigau E., Morsli K., Dossou J., Chavaudra N., Sanfilippo N., Bourhis J., Eschwège F., Parmentier C., 2002. International Journal of Radiation Oncology, Biology, Physics, 52 (5) pp. 1186-1195.
[Pmid][serval:BIB_EC64CAAF7E2A]
 
Effect of Ku80 depletion on the preintegrative steps of HIV-1 replication in human cells.
Jeanson L., Subra F., Vaganay S., Hervy M., Marangoni E., Bourhis J., Mouscadet J.F., 2002. Virology, 300 (1) pp. 100-108. Peer-reviewed.
[WoS][Pmid][serval:BIB_F18A8A5276A5]
 
Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E., Martin L., Calais G., Tuchais C., Bourhis J., Rhein B., Feham N., Alphonsi M., 2002. Seminars in Oncology, 29 (6 Suppl 19) pp. 57-60. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9AEDA9F9C96F]
 
Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J., Rosine D., 2002. Seminars in Oncology, 29 (6 Suppl 19) pp. 61-62. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF947CAF5820]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University